ORKA vs PCVX Stock Comparison
ORKA currently leads PCVX in this stock comparison, with AIQ scores of 77 vs 66. The clearest difference is quality.
What is the main difference between ORKA and PCVX?
ORKA leads the current stock comparison as Oruka Therapeutics, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Oruka Therapeutics, Inc. vs Vaxcyte, Inc.
ORKA leads
ORKA leads by 11 AIQ points, primarily on Quality, and the lead has widened from 1 points over 30 sessions. Wall Street currently favors PCVX on target upside.
Competitive: 3 of 5 evidence groups support ORKA, its lead is widening, and its current signal state is conflicted.
Oruka Therapeutics, Inc.
Vaxcyte, Inc.
The Algovestiq AIQ Score currently favors ORKA over PCVX, 77 versus 66 as of Nov 15, 2026. ORKA's advantage is driven primarily by stronger quality. ORKA also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PCVX. 3 of 5 covered evidence groups favor ORKA today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. ORKA lead: Strengthening — the AIQ differential moved from 1 to 11 points over 30 sessions.
Compare Oruka Therapeutics, Inc. and Vaxcyte, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare ORKA and PCVX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality83 vs 54ORKA +29
- Momentum81 vs 81Even
- Risk Resilience53 vs 53Even
3 of 5 evidence groups favor ORKA. ORKA’s edge is concentrated in quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +2
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.68x)
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-18.8%)
- RSI Midline Rejection — bearish, momentum, short horizon
ORKA's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — ORKA and PCVX both carry a full feed there.
The central trade-off
ORKA (Oruka Therapeutics, Inc.): the stronger current systematic profile, led by quality.
PCVX (Vaxcyte, Inc.): the counter-case, on analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ORKAORKA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ORKAORKA on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
PCVXPCVX carries the lower 1-month annualized volatility.
Analyst upside
PCVXPCVX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors ORKA, analyst targets favor PCVX. That disagreement is the most useful thing on this page.
| Measure | ORKA | PCVX | Note |
|---|---|---|---|
| Implied upside to target | +9.2% | +93% | PCVX has more room |
| Target dispersion | +13% | +4.1% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 13 | 11 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor ORKA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ORKA | 77 vs 66 |
| Fundamentals | ORKA | revenue growth 0% vs 0%; EPS growth 4.5% vs -1%; TTM ROE -4.2% vs -11.9%; gross margin 0% vs 0%; operating margin 0% vs 0% |
| Valuation | Not covered | Not covered |
| Technicals | ORKA | Price vs 50-day 17.5% vs 1.8%; vs 200-day 45% vs 9.8% |
| Risk Resilience | Even | Risk Resilience 53 vs 53 |
| Analyst expectations | PCVX | Target upside 9.2% vs 93% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ORKA and PCVX and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 11 points.
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ORKA.
How the comparison changed
45 daily snapshots · Sep 14 – Nov 13ORKA lead: Strengthening — the AIQ differential moved from 1 to 11 points over 30 sessions.
- Today
- ORKA +11
- 77 vs 66
- 7 sessions ago
- ORKA +10
- 76 vs 66
- 30 sessions ago
- ORKA +1
- 68 vs 67
- 90 sessions ago
- Not covered
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 1 bearish / 1 neutral, conflicted
Only ORKA
- Low Volume Rally Warning — bearish, volume, short horizon (0.68x)
5 bullish / 2 bearish / 1 neutral, conflicted
Only PCVX
- Beta Spike Warning — bearish, risk_regime, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-18.8%)
- RSI Midline Rejection — bearish, momentum, short horizon
Both carry 5 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, TRIX Bullish Signal, Uptrend Structure Active.
ORKA leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.34%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.04%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PCVX closes the Quality gap — currently 29 points behind, the largest single contributor to ORKA's edge.
- 2PCVX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3ORKA's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ORKA leads on balance| Metric | ORKA | PCVX |
|---|---|---|
| Revenue growth (YoY) | 0% | 0% |
| EPS growth (YoY) | 4.5% | -1% |
| Gross margin | 0% | 0% |
| Operating margin | 0% | 0% |
| Return on equity (TTM) | -4.2% | -11.9% |
| Debt to equity | 0 | 0.09 |
Performance
ORKA leads 5 of 6 windows| Metric | ORKA | PCVX |
|---|---|---|
| 1 week (5 sessions) | 2.4% | -0.8% |
| 1 month (20 sessions) | 46.5% | -0.4% |
| 3 months (63 sessions) | -6.5% | 5.2% |
| 6 months (126 sessions) | 70.1% | 21% |
| Year to date | 247.6% | 37.3% |
| 1 year (252 sessions) | 272.3% | 37.5% |
Technicals
ORKA has the stronger structure| Metric | ORKA | PCVX |
|---|---|---|
| RSI (14) | 64.4 | 49.5 |
| ADX (14) | 35.2 | 26.6 |
| Price vs 50-day | 17.5% | 1.8% |
| Price vs 200-day | 45% | 9.8% |
| Volatility (1M, annualized) | 64.3% | 58.3% |
Risk
Split| Metric | ORKA | PCVX |
|---|---|---|
| Beta | 1.4 | 1.26 |
| Sharpe ratio | 2.29 | 0.79 |
| Sortino ratio | 4.3 | 1.39 |
| Max drawdown | -36.4% | -28% |
| Current drawdown | -6.8% | -14.2% |
| Annualized volatility | 69.1% | 56.2% |
| Value at risk (95%) | -5.3% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ORKA or PCVX?
On the Algovestiq AIQ Score, ORKA is the stronger of the two as of Nov 15, 2026, scoring 77 against PCVX's 66. The edge comes from quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ORKA or PCVX the better buy right now?
ORKA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor ORKA over PCVX?
The composite weights Quality, Value, Momentum and Risk Resilience. ORKA leads Quality by 29 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ORKA or PCVX?
Analyst price targets imply +9.2% upside for ORKA and +93% for PCVX, so the Street currently favors PCVX. That points the opposite way to the AIQ Score, which favors ORKA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ORKA or PCVX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ORKA or PCVX?
ORKA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ORKA or PCVX?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ORKA or PCVX?
PCVX is the more resilient of the two, so the other name carries the higher downside risk. PCVX carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ORKA more profitable than PCVX?
ORKA leads on the comparable margin measures — gross margin 0% vs 0%; operating margin 0% vs 0%; ttm roe -4.2% vs -11.9%.
Is ORKA's lead over PCVX getting stronger or weaker?
ORKA lead: Strengthening — the AIQ differential moved from 1 to 11 points over 30 sessions. This is measured from 45 daily comparison snapshots between 2026-09-14 and 2026-11-13. The lead has not changed hands in that window.
What would change the ORKA vs PCVX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PCVX closes the Quality gap — currently 29 points behind, the largest single contributor to ORKA's edge; PCVX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ORKA's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about ORKA and PCVX?
ORKA: 4 bullish / 1 bearish / 1 neutral, conflicted. PCVX: 5 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ORKA is Golden Cross Active (bullish, long horizon). On PCVX it is Golden Cross Active (bullish, long horizon).
Compare ORKA and PCVX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.